Bausch+Lomb Results Presentation Deck
4Q22 & FY22 Accomplishments
Bausch + Lomb
(4Q22 vs. 4Q21 and FY22 vs. FY21)
0%
5%
5%
4Q22 & FY22
Reported Revenue
Surgical
19%
4Q22 & FY22
Organic Revenue ¹,2
4Q22 & FY22
Constant Currency¹
Ophthalmic
Pharmaceuticals
18%
BAUSCH + LOMB
Vision Care
63%
Continued Momentum
in Key Portfolios
+10%
reported revenue growth in
Ocuvite® + PreserVision® vs.
FY21; Grew market share in
U.S. by 170bps and 120bps,
respectively, vs. FY21³
+10%
reported revenue growth
in Biotrue® Solutions
Franchise vs. FY21
Grew market share by
360bps vs. FY21³
Investing in
Categories Growing
Faster Than Market
-50%
U.S. weekly market share for
Lumify® in Redness Reliever
Category4; Strong early launch
in Canada and acquired rights
in 18 additional countries
46%
reported revenue growth for
SiHy dailies vs. FY21
Multi-focal and toric launch
expected in 2023-2024
1. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios.
2. Organic revenue growth/change, a non-GAAP ratio, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.
3. National Consumer Panel from IRI..
Expanding Into New
Product Categories
4. IRI Panel Omnichannel. As of 4022.
In January 2023, we acquired AcuFocus, Inc.
6. In July 2022, we entered into certain strategic agreements with Sanoculis Ltd. ("Sanoculis"), including an exclusive European distribution agreement for Sanoculis Minimally Invasive Micro Sclerostomy.
Sanoculis
AcuFocus
AcuFocus - IC-8® Apthera TM IOL5
Sanoculis MIMSⓇ6
2 out of 6 acquisitions/licensing
transactions since IPO to
enhance pipeline
Seventh consecutive quarter of organic revenue growth ¹,2
Second consecutive quarter of organic revenue growth ¹,2 across all three segments
6
new product launches
including Xipere® and
Revive TM along with
geo-expansion for
Lumify® and VyzultaⓇ
7View entire presentation